Earnings MissSTIM missed estimates with Q3/24 revenue of $18.5M, below both the analyst's estimate and consensus, driven by a miss in treatment session revenue.
Operational ChallengesLingering issues related to reimbursement and customer cash flow continue to impact STIM, leading management to significantly reduce its FY24 guidance.
Revenue GuidanceThe company's third quarter reflected a top-line miss, and the full-year 2024 guidance was reduced at the midpoint, indicating ongoing challenges.